Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration

This study tests whether subthreshold laser treatment — a form of laser therapy that is below the level that causes visible damage to the retina — can slow the progression of reticular pseudodrusen (RPD), a pattern of deposits under the retina that is associated with age-related macular degeneration (AMD). AMD is the leading cause of vision loss in older adults, and RPD carries a high risk of progression to more advanced disease. Current treatments for AMD do not specifically target RPD. Participants will receive the subthreshold laser treatment to one eye and be followed over time with imaging and vision testing to see whether the treatment slows disease progression compared to an untreated eye. You may be eligible if: - You are 50 years or older (55+ per study protocol) - You have reticular pseudodrusen secondary to AMD - Your best-corrected vision is between 20/20 and 20/400 - You have clear ocular media (no cataracts or vitreous bleeding obstructing the view) - You can provide consent and attend follow-up visits You may NOT be eligible if: - You have geographic atrophy or choroidal neovascularization (wet AMD) - You have had prior AMD treatments (other than antioxidants) - You have had prior thermal laser treatment to the macula or vitrectomy - You are a woman of childbearing potential not using highly effective contraception - You have participated in another investigational drug study within 6 months Talk to your doctor to see if this trial is right for you.